105 related articles for article (PubMed ID: 18592095)
1. Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide.
Garcia JA; Incerpi EK
Arq Bras Cardiol; 2008 Jun; 90(6):409-16. PubMed ID: 18592095
[TBL] [Abstract][Full Text] [Related]
2. The potential role of nitric oxide in the hypertrophic growth of the left ventricle.
Simko F; Simko J
Physiol Res; 2000; 49(1):37-46. PubMed ID: 10805403
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis.
Wollert KC; Drexler H
Heart Fail Rev; 2002 Oct; 7(4):317-25. PubMed ID: 12379817
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase.
Belge C; Hammond J; Dubois-Deruy E; Manoury B; Hamelet J; Beauloye C; Markl A; Pouleur AC; Bertrand L; Esfahani H; Jnaoui K; Götz KR; Nikolaev VO; Vanderper A; Herijgers P; Lobysheva I; Iaccarino G; Hilfiker-Kleiner D; Tavernier G; Langin D; Dessy C; Balligand JL
Circulation; 2014 Jan; 129(4):451-62. PubMed ID: 24190960
[TBL] [Abstract][Full Text] [Related]
5. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Xu X; Zhang P; Kwak D; Fassett J; Yue W; Atzler D; Hu X; Liu X; Wang H; Lu Z; Guo H; Schwedhelm E; Böger RH; Chen P; Chen Y
Basic Res Cardiol; 2017 Aug; 112(5):55. PubMed ID: 28819685
[TBL] [Abstract][Full Text] [Related]
6. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
Gao S; Long CL; Wang RH; Wang H
Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
[TBL] [Abstract][Full Text] [Related]
7. The valosin-containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload.
Zhou N; Ma B; Stoll S; Hays TT; Qiu H
Aging Cell; 2017 Oct; 16(5):1168-1179. PubMed ID: 28799247
[TBL] [Abstract][Full Text] [Related]
8. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.
Janssens S; Pokreisz P; Schoonjans L; Pellens M; Vermeersch P; Tjwa M; Jans P; Scherrer-Crosbie M; Picard MH; Szelid Z; Gillijns H; Van de Werf F; Collen D; Bloch KD
Circ Res; 2004 May; 94(9):1256-62. PubMed ID: 15044322
[TBL] [Abstract][Full Text] [Related]
9. Modulatory role of nitric oxide in cardiac performance.
Smiljić S; Nestorović V; Savić S
Med Pregl; 2014; 67(9-10):345-52. PubMed ID: 25546983
[TBL] [Abstract][Full Text] [Related]
10. Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility.
Pasipoularides A
J Cardiovasc Transl Res; 2016 Aug; 9(4):374-99. PubMed ID: 27184804
[TBL] [Abstract][Full Text] [Related]
11. KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Yeh JL; Liu CP; Hsu JH; Tseng CJ; Wu PJ; Wang YY; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2012 Nov; 28(11):567-76. PubMed ID: 23140764
[TBL] [Abstract][Full Text] [Related]
12. Apelin Is a Negative Regulator of Angiotensin II-Mediated Adverse Myocardial Remodeling and Dysfunction.
Zhang ZZ; Wang W; Jin HY; Chen X; Cheng YW; Xu YL; Song B; Penninger JM; Oudit GY; Zhong JC
Hypertension; 2017 Dec; 70(6):1165-1175. PubMed ID: 28974565
[TBL] [Abstract][Full Text] [Related]
13. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy.
Depre C; Wang Q; Yan L; Hedhli N; Peter P; Chen L; Hong C; Hittinger L; Ghaleh B; Sadoshima J; Vatner DE; Vatner SF; Madura K
Circulation; 2006 Oct; 114(17):1821-8. PubMed ID: 17043166
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Modulation by Medium-Chain Triglycerides Reduces Oxidative Stress and Ameliorates CD36-Mediated Cardiac Remodeling in Spontaneously Hypertensive Rat in the Initial and Established Stages of Hypertrophy.
Saifudeen I; Subhadra L; Konnottil R; Nair RR
J Card Fail; 2017 Mar; 23(3):240-251. PubMed ID: 27530817
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol prevents pathological but not physiological cardiac hypertrophy.
Dolinsky VW; Soltys CL; Rogan KJ; Chan AY; Nagendran J; Wang S; Dyck JR
J Mol Med (Berl); 2015 Apr; 93(4):413-25. PubMed ID: 25394677
[TBL] [Abstract][Full Text] [Related]
16. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation.
Ruiz-Hurtado G; Fernández-Velasco M; Mourelle M; Delgado C
Hypertension; 2007 Dec; 50(6):1049-56. PubMed ID: 17984372
[TBL] [Abstract][Full Text] [Related]
17. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload.
Beetz N; Rommel C; Schnick T; Neumann E; Lother A; Monroy-Ordonez EB; Zeeb M; Preissl S; Gilsbach R; Melchior-Becker A; Rylski B; Stoll M; Schaefer L; Beyersdorf F; Stiller B; Hein L
J Mol Cell Cardiol; 2016 Dec; 101():145-155. PubMed ID: 27789290
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of endothelial nitric oxide synthase in the myocardium ameliorates the progression of left ventricular hypertrophy in L-arginine treated Wistar-Kyoto rats.
Ahmad A; Sattar MA; Rathore HA; Abdulla MH; Khan SA; Abdullah NA; Johns EJ
J Physiol Pharmacol; 2016 Feb; 67(1):31-44. PubMed ID: 27010893
[TBL] [Abstract][Full Text] [Related]
19. Compensatory remodeling of coronary microvasculature maintains shear stress in porcine left-ventricular hypertrophy.
Huo Y; Kassab GS
J Hypertens; 2012 Mar; 30(3):608-16. PubMed ID: 22252479
[TBL] [Abstract][Full Text] [Related]
20. Expression and tissue localization of beta-catenin, alpha-actinin and chondroitin sulfate proteoglycan 6 is modulated during rat and human left ventricular hypertrophy.
Ridinger H; Rutenberg C; Lutz D; Buness A; Petersen I; Amann K; Maercker C
Exp Mol Pathol; 2009 Feb; 86(1):23-31. PubMed ID: 19094982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
